Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S
First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Clin Exp Immunol. 2000 Sep;121(3):437-43. doi: 10.1046/j.1365-2249.2000.01324.x.
Levels of platelet-derived microparticles (PMPs), platelet activation markers (P-selectin expressed on, or annexin V binding to, platelets (plt:P-selectin or plt:annexin V, respectively)), chemokines (IL-8, monocyte chemotactic peptide-1 (MCP-1), and regulated on activation normally T-cell expressed and secreted (RANTES)), and soluble P- and E-selectins were compared in peripheral blood from diabetic and control patients in order to develop a better understanding of their potential contribution to diabetic vascular complications. Significant increases were found for PMPs, plt:P-selectin, MCP-1, RANTES and soluble P- and E-selectins in diabetic individuals, whereas IL-8 levels were similar. Furthermore, after ticlopidine treatment, most of these factors receded to baseline levels observed in non-diabetic patients. Our findings indicate that ticlopidine might be able to prevent or reduce vascular complications in diabetic patients.
为了更好地了解血小板衍生微粒(PMPs)、血小板活化标志物(分别为血小板上表达的P-选择素或血小板与膜联蛋白V结合(plt:P-选择素或plt:膜联蛋白V))、趋化因子(白细胞介素-8(IL-8)、单核细胞趋化蛋白-1(MCP-1)和正常T细胞激活时表达和分泌的调节因子(RANTES))以及可溶性P-选择素和E-选择素在糖尿病患者和对照患者外周血中的水平,对其进行了比较。结果发现,糖尿病患者的PMPs、plt:P-选择素、MCP-1、RANTES以及可溶性P-选择素和E-选择素显著增加,而IL-8水平相似。此外,噻氯匹定治疗后,这些因素大多降至非糖尿病患者观察到的基线水平。我们的研究结果表明,噻氯匹定可能能够预防或减少糖尿病患者的血管并发症。